Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. reports developments as a clinical-stage biopharmaceutical company focused on FLAMINGO-01, a Phase III clinical trial evaluating GLSI-100 as an immunotherapy intended to prevent breast cancer recurrences. GLSI-100 combines the GP2 peptide with GM-CSF and is described by the company as a Fast Track designated program.
Recurring news includes FLAMINGO-01 clinical-site activity, oncology conference abstracts and posters, open-label immune-response and recurrence-rate data, patent-claim updates tied to GP2, at-the-market equity financing activity, and SEC reporting or Nasdaq compliance matters related to periodic filings.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) outlined progress on its Phase III clinical trial, FLAMINGO-01, aimed at evaluating GLSI-100, an immunotherapy for breast cancer recurrence prevention. The trial is now recruiting at over 15 large university hospitals. An open-label arm is introduced to broaden immune response data. Interim analysis is anticipated in about three years. The company is also advancing commercial manufacturing for potential regulatory submissions, enhancing prospects for conditional market approval based on positive interim findings.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has released an updated corporate presentation focused on GP2, an immunotherapy to prevent breast cancer recurrences. The presentation includes a combined analysis of 5-year Phase IIb data, showcasing no recurrences in patients treated with GP2. CEO Snehal Patel highlighted interest from major institutions for potential collaborations, licensing, and expansion of clinical trials in Europe. The company plans to commence a Phase III clinical trial following promising Phase IIb results, where GP2 was well-tolerated with no serious adverse events.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced its partnership as a Bronze sponsor for the Susan G. Komen Race for the Cure in Houston on October 2, 2021. The company will manage a water station and actively participate in the event. This collaboration underscores Greenwich's commitment to supporting breast cancer patients and survivors. The CEO emphasized the alignment of their goal to prevent metastatic breast cancer recurrence with the mission of the Komen foundation. The event aims to raise funds for breast cancer advocacy and research.
Greenwich LifeSciences (GLSI) announced that CEO Snehal Patel will present at the Benzinga Healthcare Small-Cap Conference on September 29-30, 2021. Patel's presentation is scheduled for September 29 at 9:30 am ET. The conference will connect investors with small-cap companies and features live presentations and educational sessions. Greenwich LifeSciences is focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences. Notably, in a Phase IIb trial, GP2 showed no recurrences after five years in treated patients.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) participates in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021. CEO Snehal Patel will present virtually on September 29 at 2:00 PM ET and engage in one-on-one meetings with investors. The conference features over 300 companies and a keynote by Pfizer's CEO, Albert Bourla. Greenwich develops GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery, with promising Phase IIb trial results showing no recurrences after 5 years.
Greenwich LifeSciences, Inc. (GLSI) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Snehal Patel will present on demand starting September 13 and engage in one-on-one meetings with investors. The conference will feature key industry speakers and networking opportunities. Greenwich’s main focus is on its innovative GP2 immunotherapy aimed to prevent breast cancer recurrences, supported by successful Phase IIb clinical trial results.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, reports its significant achievements, including a 763% increase in share price since its IPO in February 2019, the highest among 307 biotech IPOs. The company is pleased with H.C. Wainwright's analyst coverage initiation on September 1, 2021, with a price target of $78 per share. It has also been added to the Russell 2000 index, enhancing its visibility to institutional investors. Upcoming updates on GP2 immunotherapy and Phase III clinical trial initiation are anticipated.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its participation in Citi's 16th Annual BioPharma Virtual Conference, taking place from September 8-10, 2021. CEO Snehal Patel will engage in one-on-one meetings with investors. The conference features key discussions and presentations from leading pharma and biotech companies. Greenwich focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrences. Previous Phase IIb trials showed no recurrences in high HER2 positive patients after treatment, and a Phase III trial is planned.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 28, 2021. This milestone is expected to boost institutional ownership and visibility for the company as it develops GP2, an immunotherapy aimed at preventing breast cancer recurrences. CEO Snehal Patel emphasized the significance of this addition and the plans for a Phase III clinical trial. The Russell Indexes are benchmarks for $10.6 trillion in assets, highlighting the potential for increased interest in GLSI.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) presented the final 5-year safety data of its GP2 immunotherapy at the 2021 ASCO Annual Meeting. The Phase IIb trial showed no serious adverse events related to GP2, with the majority experiencing mild injection site reactions. Notably, completion of the GP2 Primary Immunization Series led to a 0% recurrence rate in HER2 3+ patients over five years post-surgery. The findings support plans for a Phase III trial, leveraging the encouraging safety data to attract potential partners for co-development.